12/19/2023Financial
12/04/2023Information
JSR Issues JSR Report 2023 in English
12/01/2023Sustainability
Participation in New Energy Collaborative
11/30/2023Corporate
JSR at SEMICON JAPAN 2023
11/20/2023Financial
Summary of Q&A session of Conference call(PDF:147.3 KB)
11/17/2023Sustainability
JSR Group Releases its “JSR Group Sustainability Site 2023”
11/09/2023Products
MEBGEN™ BRAF 3 Kit Receives MHLW Approval and Insurance Coverage as a Tumor Agnostic Companion Diagnostic
11/08/2023Products
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening
11/07/2023Financial
Minutes(PDF:217.8 KB)
11/06/2023Financial
Briefing Video on Financial Results
11/06/2023Financial
Notice Concerning Revision of Consolidated Earnings Forecasts for the Fiscal Year Ending March 2024(PDF:165.6 KB)
11/06/2023Financial
Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2024(PDF:707.7 KB)
11/06/2023Financial
JSR 23Q2_Presentation Material for earnings announcement(PDF:734.6 KB)
10/11/2023Corporate
Annual Report 2023 is now Available
09/13/2023Products
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and Manufacturing ~ Offering extends legacy of SUREtechnology Platform™ for more efficient workflows and simplified processes ~
09/12/2023Corporate
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
08/30/2023Financial
Announcement Regarding Appointment of Tender Offer Agent for Tender Offer for JSR Corporation (Securities Code 4185) by JICC-02, Ltd.(PDF:169.4 KB)
08/29/2023Financial
Summary of Q&A session of Conference call(PDF:150.5 KB)
08/24/2023Corporate
A collaborative work between Crown Bioscience and HanX Biopharma published in Nature's Scientific Reports
08/09/2023Financial
Minutes(PDF:209.1 KB)
08/07/2023Information
Eric Johnson, CEO and President, has been elected to the board of SEMI
08/07/2023Financial
Briefing Video on Financial Results
08/07/2023Financial
Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2024(PDF:826.8 KB)
08/07/2023Financial
JSR 23Q1_Presentation Material for earnings announcement(PDF:650.9 KB)
07/19/2023Financial
Q&A Summary of a Call regarding “Overview of Opinion on Scheduled Commencement of the Tender Offer by JICC-02, Ltd.”(PDF:196.7 KB)
07/06/2023Corporate
JSR Active Innovation Fund LLC invests in Gaianixx Inc., which develops single-crystal films for semiconductors
07/06/2023Financial
(Updated) Notice Regarding Partial Amendments to Announcement of Opinion on Scheduled Commencement of the Tender Offer and Recommendation for our Shareholders to Tender their Shares in the Tender Offer to be Conducte(PDF:269.5 KB)
06/27/2023Financial
Announcement Regarding Planned Commencement of Tender Offer for JSR Corporation (Securities Code 4185) by JICC-02, Ltd.(PDF:673.8 KB)
06/27/2023Financial
Announcement of Opinion on Scheduled Commencement of the Tender Offer and Recommendation for our Shareholders to Tender their Shares in the Tender Offer to be Conducted by JICC-02, Ltd. for the Shares in JSR Corporati(PDF:430.4 KB)
06/26/2023Financial
Overview of Opinion on Scheduled Commencement of the Tender Offer by JICC-02, Ltd.(Video)
06/26/2023Financial
Overview of Opinion on Scheduled Commencement of the Tender Offer by JICC-02, Ltd.(PDF:374.8 KB)
06/26/2023Financial
Notice Regarding Revisions to Dividend for the Fiscal Year Ending March 2024 (No Dividend)(PDF:147.9 KB)
06/26/2023Financial
Extraordinary Report(on voting results) for the 78th Ordinary Meeting of Shareholders(PDF:210.1 KB)
06/24/2023Financial
Notice Regarding Media Articles Regarding Acquisition of Our Shares by Japan Investment Corporation(PDF:76.6 KB)
06/19/2023Corporate
JSR Partners with Hokkaido University for Production and Sales of Functional Lipids for Lipid Nanoparticle DDS
06/19/2023Corporate
MBL hold ribbon cutting of a new R&D facility for Cell Therapy in Beijing, China.
06/16/2023Financial
Notice of the Resolution of the 78th Ordinary General Meeting of Shareholders(PDF:255.1 KB)
06/09/2023Financial
Results of Evaluation of the Effectiveness of the Board of Directors(PDF:197.7 KB)
06/06/2023Products
KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical Manufacturing
06/01/2023Corporate
Announcement of Operational Consolidation of KBI Biopharma, Inc. and Selexis SA
05/29/2023Corporate
JSR's interfacial molecular binder "MOLTIGHT IMB" won "The 19th JPCA Award" !
05/25/2023Financial
Summary of Q&A session of Conference call(PDF:144.0 KB)
05/24/2023Information
Beware of False Job Postings
05/19/2023Financial
Notice of Convening the 78th Ordinary General Meeting of Shareholders(PDF:3.5 MB)
05/09/2023Financial
Notice of Change of Directors and Officers(PDF:182.8 KB)
05/09/2023Financial
Notice regarding Transfer of Representative Directors(PDF:120.7 KB)
04/27/2023Financial
Briefing Video on Financial Results
04/27/2023Financial
Minutes(PDF:225.8 KB)
04/27/2023Financial
Notice regarding Difference between Forecasts and Actual Results(PDF:187.7 KB)
04/27/2023Financial
Consolidated Financial Results for the year ended March 2023(PDF:2.1 MB)
04/27/2023Financial
JSR 22Q4_Presentation Material for earnings announcement(PDF:914.1 KB)
04/18/2023Corporate
KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO
04/05/2023Corporate
Crown Bioscience completes acquisition of IndivuServ business unit of Indivumed GmbH
04/03/2023Corporate
JSR begins development of raw materials from biomass Concluded a joint development agreement with Bacchus Bio innovation Co., Ltd.
03/22/2023Products
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility
03/22/2023Financial
QA Summary of FY2022 Briefing session regarding Life Sciences business(PDF:163.4 KB)
03/15/2023Products
FLOSFIA and JSR progress toward practical use of the world's first P-type semiconductor, Iridium Gallium Oxide -- Development of new iridium-based film formation materials for mass production creates a solution for realizing the ultimate SEMI ecology™ -
03/10/2023Corporate
Crown Bioscience opens new lab in Singapore, sets up commercial partners there
03/10/2023Financial
FY2022 Briefing session regarding Life Sciences business(Video)
03/10/2023Financial
FY2022 Briefing session regarding Life Sciences business(PDF:1.9 MB)
03/06/2023Financial
Summary of Q&A session of Conference call(PDF:175.5 KB)
03/01/2023Sustainability
Support for the people and areas affected by the Turkey-Syria Earthquake
02/15/2023Corporate
This Rare Metal Could Produce Large Spin Current
02/15/2023Products
JSR Life Sciences, LLC entered into a subcontract with Novel351k to co-develop biosimilar programs
02/14/2023Financial
Briefing Video on Financial Results
02/06/2023Financial
Minutes(PDF:273.1 KB)
02/06/2023Financial
Notice regarding Revision of Projections for Consolidated Financial Results(PDF:272.0 KB)
02/06/2023Financial
Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023(PDF:723.7 KB)
02/06/2023Financial
JSR 22Q3_Presentation Material for earnings announcement(PDF:663.5 KB)
02/01/2023Corporate
JSR Received the "2022 TSMC Excellent Performance Awards" from TSMC
02/01/2023Products
JSR Withdraws from Agency Contract with Carbon 3D Printing Business
01/26/2023Corporate
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
01/25/2023Products
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
01/19/2023Products
JSR at INTER NEPCON JAPAN 2023
01/11/2023Corporate
Announcement regarding acquisition of JSR Electronic Materials Korea
01/01/2023Corporate